Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35500404/
doi: 10.1016/j.ejca.2022.03.004. 1 Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan. Electronic address: [email protected]. 2 Department of Medical Oncology, The Cancer Institute Hospital of Japanese...
Conclusion: E7389-LF was tolerable and favourable antitumour activity was observed, particularly in patients with HR BC. Prophylactic pegfilgrastim can be considered in patients at high risk for neutropenia and febrile neutropenia.
Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial
Source : https://www.tandfonline.com/doi/abs/10.1080/03009742.2022.2050502?journalCode=irhe20
To study the long-term effect of 16 weeks of etanercept treatment on disease activity and radiographic changes in patients with suspected non-radiographic axial spondyloarthritis (nr-axSpA). Eighty patients with inflammatory back...
Conclusion: A short course of etanercept in patients with suspected nr-axSpA did not affect disease activity, the chance of biological treatment, or radiographic progression after 3 years of follow-up.
Dynamics of biosimilar uptake in emerging markets
Source : https://www.tandfonline.com/doi/abs/10.1080/14712598.2022.2076557?journalCode=iebt20
Abstract Globally, biosimilars are expected to play a key role in lowering healthcare costs and providing increased patient access to biological therapies. Given this, and in line with the European...
Expert opinion: Implementation of pricing and procurement policies, as well as provider and patient confidence in biosimilar efficacy, are key factors in their uptake. Due to the high cost of biosimilar development, incentivizing domestic companies with the biosimilar manufacturing capability to produce these drugs will be helpful in ensuring...
Bridging Fixed Dose to Body Weight-Based Regimen of Adalimumab in Pediatric Ulcerative Colitis Using a Pharmacometric Modeling Approach: Case Study with the Phase 3 ENVISION I Trial
You do not currently have access to this article. Subscription prices and ordering for this journal Bridging Fixed Dose to Body Weight-Based Regimen of Adalimumab in Pediatric Ulcerative Colitis Using...
Conclusions: The population pharmacokinetic/pharmacodynamic model supports the appropriateness of the use of fixed dosing regimen in the pediatric ulcerative colitis population.
Whole-exome sequencing in a subject with fluctuating neuropsychiatric symptoms, immunoglobulin G1 deficiency, and subsequent development of Crohn's disease: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35538558/
Loss-of-function mutation of NRLRP12 gene augments production of interleukin-1β and tumor necrosis factor-α, while gain-of-function mutation of IRF2BP2 impairs cytokine production and B cell differentiation. We propose that the presence...
Relevance: At 15 years of age, she was diagnosed with Crohn's disease, following onset of acute abdomen. Treatment with oral corticosteroid and then tumor necrosis factor-α blockers (adalimumab and infliximab) led to remission of Crohn's disease.